City

Chengdu (1)

Dallas (1)

Overall Status

Recruiting (2)

Sign in for free

Phase

n/a (1)

phase 2 (1)

Sponsor

University of Texas Southwestern Medical Center (1)

West China Hospital (1)

Collaborator

Howard Hughes Medical Institute (1)

National Cancer Institute (NCI) (1)

Intervention

13c-acetate (1)

13c-fructose (1)

13c-glucose (1)

13c-glutamine (1)

13c-lactate (1)

sintilimab injection plus inlyta treatment (1)

Study Documents

Intervention Type

drug (1)

other (1)

Funder Type

Other (2)

Study Type

Interventional (2)

fumarate hydratase deficiency

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Kidney Cancer, Renal Cell Carcinoma, Clear Cell Carcinoma Trial in Dallas (13C-Glucose, 13C-Acetate, 13C-Lactate)

Recruiting

Kidney Cancer
+11 more

13C-Glucose
+4 more

Dallas, Texas

University of Texas Southwestern Medical Center

Dec 1, 2022

Carcinoma, Renal Cell, Fumarate Hydratase Deficiency, Immunotherapy Trial in Chengdu (Sintilimab injection plus Inlyta

Recruiting

Carcinoma, Renal Cell
+2 more

Sintilimab injection plus Inlyta treatment

Chengdu, Sichuan, China

West China Hospital

Jul 11, 2021